Extending telomeres to extend the human healthspan

At Rejuvenation we're resetting a key mechanism of aging

Telomeres are an aging clock

Our breakthrough drug

Pipeline

We have a robust pipeline focused on aging and fatal diseases in which short telomeres have causal or major exacerbating roles.  We are developing these programs in-house and through partnerships and out-licensing. 

Team

Our strategy is to make safe rapid telomere extension available as broadly and quickly as possible

ramunas - circle - 500x500px

John Ramunas

Founder & CEO, Stanford PhD, Co-inventor, Decade of experience with mRNA for therapeutic applications. Thesis title: Telomere extension to extend human healthspan.

glenn circle - 500 px

Glenn Markov

Founder & COO, Stanford PhD, Decade of experience in genetics and epigenetics of cellular reprogramming.

Will-800pxw-

Will Olsen

VP of Development Operations, Founder of liver diagnostics company, Luminist (acquired by DiscernDx). Decade of drug and device development experience.

blau

Helen M. Blau

Founder & Advisor, Co-inventor, Professor at Stanford University, discovered that short telomeres underlie the fatal etiology of multiple monogenic diseases.

Apoorva Shankar

Apoorva Shankar

Life Science Research Associate, MSc in Biotechnology.

Kyle

Kyle Brewer

Research Scientist, Postdoc at Stanford University on the proteomics of aging in the liver and brain, PhD in Biophysics at UT Southwestern on neurotransmitter release. 

Bo Yang

Bo Yang

Research Fellow, MD, MSc, PhD, CTBS, Clinical and Preclinical Development at Boehringer Ingelheim and Gilead.  Postdoc at Yale University on novel roles of ion transport proteins.

Robin

Robin E. Holbrook

Director of Finance and Administration, Stanford AB in Cultural Anthropology,  30+ years of F&A experience supporting research excellence at Stanford School of Medicine.

Contact Us

Email

Patient inquiries:  patients@rejuvenationtech.com 

General inquiries:  info@rejuvenationtech.com 

Employment inquiries:  jobs@rejuvenationtech.com 

Investor inquiries:  investors@rejuvenationtech.com